Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Koji Yoshimoto, Masahiro Mizoguchi, Nobuhiro Hata, Toshiyuki Amano, Akira Nakamizo & Tomio Sasaki. (2012) Molecular biomarkers of glioblastoma: current targets and clinical implications. Current Biomarker Findings 2, pages 63-76.
Read now
Read now
Catherine A Del Vecchio, Gordon Li & Albert J Wong. (2012) Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Review of Vaccines 11:2, pages 133-144.
Read now
Read now
Christopher Schutt, Klaus Bumm, Leonardo Mirandola, Giovanni Bernardini, Nicholas D’ Cunha, Lukman Tijani, Diane Nguyen, Joehassin Cordero, Marjorie R. Jenkins, Everardo Cobos, W. Martin Kast & Maurizio Chiriva-Internati. (2012) Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. International Reviews of Immunology 31:1, pages 22-42.
Read now
Read now
Manasi Das, Chandana Mohanty & Sanjeeb K Sahoo. (2009) Ligand-based targeted therapy for cancer tissue. Expert Opinion on Drug Delivery 6:3, pages 285-304.
Read now
Read now
Articles from other publishers (58)
Rishab Ramapriyan, Jing Sun, Annabel Curry, Leland G. Richardson, Tarun Ramesh, Matthew A. Gaffey, Patrick C. Gedeon, Elizabeth R. Gerstner, William T. Curry & Bryan D. Choi. (2023) The Role of Antibody-Based Therapies in Neuro-Oncology. Antibodies 12:4, pages 74.
Crossref
Crossref
Oliver Y. Tang, Zev A. Binder, Donald M. O’Rourke & Stephen J. Bagley. (2023) Optimizing CAR-T Therapy for Glioblastoma. Molecular Diagnosis & Therapy 27:6, pages 643-660.
Crossref
Crossref
Hesam Shahabifard, Mahdi Zarei, Keihan Kookli, Nazgol Esmalian Afyouni, Narges Soltani, Sairan Maghsoodi, Ali Adili, Javad Mahmoudi, Navid Shomali & Siamak Sandoghchian Shotorbani. (2023)
An updated overview of the application of
CAR‐T
cell therapy in neurological diseases
. Biotechnology Progress 39:5.
Crossref
Crossref
Meagan Mandabach Olivet, Michael C. Brown, Zachary J. Reitman, David M. Ashley, Gerald A. Grant, Yuanfan Yang & James M. Markert. (2023) Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults. Cancers 15:15, pages 3901.
Crossref
Crossref
Samuel Luca Rocha Pinheiro, Fabian Fellipe Bueno Lemos, Hanna Santos Marques, Marcel Silva Luz, Luís Guilherme de Oliveira Silva, Clara Faria Souza Mendes dos Santos, Karolaine da Costa Evangelista, Mariana Santos Calmon, Matheus Sande Loureiro & Fabrício Freire de Melo. (2023) Immunotherapy in glioblastoma treatment: Current state and future prospects. World Journal of Clinical Oncology 14:4, pages 138-159.
Crossref
Crossref
Samane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, Saba Hajazimian, Pouya Goleij, Javad Behroozi, Behrouz Shademan, Alireza Isazadeh & Behzad Baradaran. (2022)
Chimeric antigen receptor T (
CAR‐T
) cells: Novel cell therapy for hematological malignancies
. Cancer Medicine 12:7, pages 7844-7858.
Crossref
Crossref
Christian L. Flugel, Robbie G. Majzner, Giedre Krenciute, Gianpietro Dotti, Stanley R. Riddell, Dimitrios L. Wagner & Mohamed Abou-el-Enein. (2022) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nature Reviews Clinical Oncology 20:1, pages 49-62.
Crossref
Crossref
Mehdi Karimi-Shahri, Malihe Khorramdel, Sara Zarei, Fatemeh Attarian, Pedram Hashemian & Hossein Javid. (2022) Glioblastoma, an opportunity T cell trafficking could bring for the treatment. Molecular Biology Reports 49:10, pages 9863-9875.
Crossref
Crossref
Oliver Y. Tang, Lifeng Tian, Todd Yoder, Rong Xu, Irina Kulikovskaya, Minnal Gupta, Jan Joseph Melenhorst, Simon F. Lacey, Donald M. O’Rourke & Zev A. Binder. (2022) PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Frontiers in Immunology 13.
Crossref
Crossref
Xiao Xue Zeng, Jianwen Zeng & Baoyi Zhu. (2022) Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control. Reviews in the Neurosciences 33:3, pages 313-326.
Crossref
Crossref
Hajime Takase, Reo Tanoshima, Navneet Singla, Yoshihiko Nakamura & Tetsuya Yamamoto. (2021) Pineal parenchymal tumor of intermediate differentiation: a systematic review and contemporary management of 389 cases reported during the last two decades. Neurosurgical Review 45:2, pages 1135-1155.
Crossref
Crossref
Ya-Jui Lin, Leila A. Mashouf & Michael Lim. (2022) CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. Frontiers in Immunology 13.
Crossref
Crossref
Josephine Zhang & Jesús A Siller-Farfán. (2022) Current and future perspectives of chimeric antigen receptors against glioblastoma. Immunotherapy Advances 2:1.
Crossref
Crossref
Wanying Zeng & Pumin Zhang. (2022) Resistance and recurrence of malignancies after CAR-T cell therapy. Experimental Cell Research 410:2, pages 112971.
Crossref
Crossref
Trisha R. Berger, Alexander Boardman, Renier Brentjens & Marcela V. Maus. 2022. Gene and Cellular Immunotherapy for Cancer. Gene and Cellular Immunotherapy for Cancer
29
55
.
Athina Malliou, Athanasios P. Kyritsis & George A. Alexiou. 2022.
Yanjun Zheng, Kutty Selva Nandakumar & Kui Cheng. (2021) Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. Journal of Medicinal Chemistry 64:14, pages 9577-9591.
Crossref
Crossref
Thilan Tudor, Zev A. Binder & Donald M. O’Rourke. (2021) CAR T Cells. Neurosurgery Clinics of North America 32:2, pages 249-263.
Crossref
Crossref
Abigail L. Mende, Jessica D. Schulte, Hideho Okada & Jennifer L. Clarke. (2021) Current Advances in Immunotherapy for Glioblastoma. Current Oncology Reports 23:2.
Crossref
Crossref
Stephen J. Bagley. 2021. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
453
471
.
Sukhbir Singh, Neelam Sharma, Anil Bansal, Neha Kanojia, Sheshank Sethi, Jitender Madan & Rupinder Kaur Sodhi. 2021. Clinical Perspectives and Targeted Therapies in Apoptosis. Clinical Perspectives and Targeted Therapies in Apoptosis
153
207
.
Feifei Guo & Jiuwei Cui. (2020) CAR-T in solid tumors: Blazing a new trail through the brambles. Life Sciences 260, pages 118300.
Crossref
Crossref
Gabriel Nery de Albuquerque Rego, Arielly da Hora Alves, Mariana Penteado Nucci, Javier Bustamante Mamani, Fernando Anselmo de Oliveira & Lionel Fernel Gamarra. (2020) Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations. International Journal of Molecular Sciences 21:12, pages 4490.
Crossref
Crossref
Tsutomu Nakazawa, Atsushi Natsume, Fumihiko Nishimura, Takayuki Morimoto, Ryosuke Matsuda, Mitsutoshi Nakamura, Shuichi Yamada, Ichiro Nakagawa, Yasushi Motoyama, Young-Soo Park, Takahiro Tsujimura, Toshihiko Wakabayashi & Hiroyuki Nakase. (2020) Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. Cells 9:4, pages 998.
Crossref
Crossref
Zhidong Wang & Yu J. Cao. (2020) Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research. Frontiers in Immunology 11.
Crossref
Crossref
Aleksei Titov, Aygul Valiullina, Ekaterina Zmievskaya, Ekaterina Zaikova, Alexey Petukhov, Regina Miftakhova, Emil Bulatov & Albert Rizvanov. (2020) Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers 12:1, pages 125.
Crossref
Crossref
Stephen J. Bagley & Donald M. O’Rourke. (2020) Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. Pharmacology & Therapeutics 205, pages 107419.
Crossref
Crossref
Deng Pan, Dapeng Zhou, Weijing Cai, Weibo Wu, Wen Ling Tan, Caicun Zhou & Yanyan Lou. (2019) Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma. BMC Immunology 20:1.
Crossref
Crossref
Deeksha Saxena, Saad Sheikh, Gary Kao, Zev A Binder, Michelle Alonso-Basanta, Donald M O’Rourke, MacLean P Nasrallah & Jay F Dorsey. (2019) Rapid and ultrasensitive digital PCR (dPCR) profiling of EGFRvIII in tumor cells and tissues. Neuro-Oncology Advances 1:1.
Crossref
Crossref
Weijing Cai, Dapeng Zhou, Weibo Wu, Wen Ling Tan, Jiaqian Wang, Caicun Zhou & Yanyan Lou. (2018) MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics 19:1.
Crossref
Crossref
Stephen J Bagley, Arati S Desai, Gerald P Linette, Carl H June & Donald M O’Rourke. (2018) CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-Oncology 20:11, pages 1429-1438.
Crossref
Crossref
Zhenguang Wang, Zhiqiang Wu, Yang Liu & Weidong Han. (2017) New development in CAR-T cell therapy. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Zhenguang Wang, Yelei Guo & Weidong Han. (2017) Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein & Cell 8:12, pages 896-925.
Crossref
Crossref
An-Liang Xia, Xiao-Chen Wang, Yi-Jun Lu, Xiao-Jie Lu & Beicheng Sun. (2017) Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. Oncotarget 8:52, pages 90521-90531.
Crossref
Crossref
Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai, Jan J. Melenhorst, Keith Mansfield, Jennifer J. D. Morrissette, Maria Martinez-Lage, Steven Brem, Eileen MaloneyAngela Shen, Randi Isaacs, Suyash MohanGabriela Plesa, Simon F. Lacey, Jean-Marc Navenot, Zhaohui Zheng, Bruce L. Levine, Hideho OkadaCarl H. June, Jennifer L. BrogdonMarcela V. Maus. (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine 9:399.
Crossref
Crossref
Dong Jin, Xin Yu, Bing Chen, Zhitao Li, Jia Ding, Xiuyun Zhao & Gaofu Qi. (2017) Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model. Immunotherapy 9:7, pages 537-553.
Crossref
Crossref
Anna E. Kersh, Maiko Sasaki, Lee A. Cooper, Haydn T. Kissick & Brian P. Pollack. (2016) Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Frontiers in Pharmacology 7.
Crossref
Crossref
Jennifer S. Sims, Timothy H. Ung, Justin A. Neira, Peter Canoll & Jeffrey N. Bruce. (2015) Biomarkers for glioma immunotherapy: the next generation. Journal of Neuro-Oncology 123:3, pages 359-372.
Crossref
Crossref
Stanley S. Stylli, Rodney B. Luwor, Thomas M.B. Ware, Fiona Tan & Andrew H. Kaye. (2015) Mouse models of glioma. Journal of Clinical Neuroscience 22:4, pages 619-626.
Crossref
Crossref
Richard A. Morgan. (2013) Risky business: target choice in adoptive cell therapy. Blood 122:20, pages 3392-3394.
Crossref
Crossref
Ryan T. Nitta & Gordon Li. (2013) The Invasive Nature of Glioblastoma. World Neurosurgery 80:3-4, pages 279-280.
Crossref
Crossref
Pavel Sluka & Ian D. Davis. (2013) Cell mates: paracrine and stromal targets for prostate cancer therapy. Nature Reviews Urology 10:8, pages 441-451.
Crossref
Crossref
Kirti Gupta & Pravin Salunke. (2012) Molecular markers of glioma: an update on recent progress and perspectives. Journal of Cancer Research and Clinical Oncology 138:12, pages 1971-1981.
Crossref
Crossref
Jari I. Finneman & Mark J. Pozzo. (2012) Novel approach for optimization of a ?difficult? peptide synthesis by utilizing quantitative reaction monitoring assays. Journal of Peptide Science 18:8, pages 511-518.
Crossref
Crossref
Gordon Li, Siddhartha S. Mitra, Michelle Monje, Kristy N. Henrich, C. Dana Bangs, Ryan T. Nitta & Albert J. Wong. (2012) Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. Journal of Neuro-Oncology 108:3, pages 395-402.
Crossref
Crossref
Allison M. Cushman-Vokoun. 2012. Molecular Genetics and Personalized Medicine. Molecular Genetics and Personalized Medicine
51
101
.
Ian F. Parney. 2012. Glioma. Glioma
42
52
.
Charlotte Lund Denholt, Tina Binderup, Marie-Thérése Stockhausen, Hans Skovgaard Poulsen, Mogens Spang-Thomsen, Paul Robert Hansen, Nic Gillings & Andreas Kjær. (2011) Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology 38:4, pages 509-515.
Crossref
Crossref
Markus J. Riemenschneider, Judith W. M. Jeuken, Pieter Wesseling & Guido Reifenberger. (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica 120:5, pages 567-584.
Crossref
Crossref
Gordon Li, Siddhartha Mitra, Jason Karamchandani, Michael S.B. Edwards & Albert J. Wong. (2010) Pineal Parenchymal Tumor of Intermediate Differentiation. Neurosurgery 66:5, pages 963-968.
Crossref
Crossref
Siddhartha Mitra, Gordon Li & Griffith R. HarshIVIV. (2010) Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas. Neurosurgery Clinics of North America 21:1, pages 67-76.
Crossref
Crossref
Gordon Li, Siddhartha Mitra & Albert J. Wong. (2010) The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas. Neurosurgery Clinics of North America 21:1, pages 87-93.
Crossref
Crossref
Judith Jeuken, Angelique Sijben, Cristina Alenda, Jos Rijntjes, Marieke Dekkers, Sandra Boots-Sprenger, Roger McLendon & Pieter Wesseling. (2009) Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics. Brain Pathology 19:4, pages 661-671.
Crossref
Crossref
Hui-Wen Lo, Hu Zhu, Xinyu Cao, Amy Aldrich & Francis Ali-Osman. (2009)
A Novel Splice Variant of
GLI1
That Promotes Glioblastoma Cell Migration and Invasion
. Cancer Research 69:17, pages 6790-6798.
Crossref
Crossref
Marc A. Antonyak, Bo Li, Andrew D. Regan, Qiyu Feng, Stephanie S. Dusaban & Richard A. Cerione. (2009) Tissue Transglutaminase Is an Essential Participant in the Epidermal Growth Factor-stimulated Signaling Pathway Leading to Cancer Cell Migration and Invasion. Journal of Biological Chemistry 284:27, pages 17914-17925.
Crossref
Crossref
Hui K. Gan, Andrew H. Kaye & Rodney B. Luwor. (2009) The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience 16:6, pages 748-754.
Crossref
Crossref
Charlotte Lund Denholt, Paul Robert Hansen, Nina Pedersen, Hans Skovgaard Poulsen, Nic Gillings & Andreas Kjær. (2008) Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library. Biopolymers 91:3, pages 201-206.
Crossref
Crossref
Joachim Wahl, Klaus-Michael Debatin & Christian Beltinger. (2009) Tumorstammzellen: Grundlagen, klinische Implikationen und KontroversenCancer Stem Cells: Basics, Clinical Implications, and Controversies. Onkopipeline 1:3, pages 91-100.
Crossref
Crossref